Loading...

FITC anti-mouse CD4 Antibody FITC anti-mouse CD4 Antibody

Pricing & Availability
Clone
RM4-5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
RM4-5
C57BL/6 mouse splenocytes stained with CD4 (clone RM4-5) FITC (solid line) or rat IgG2a, κ FITC isotype control (dotted line).
  • RM4-5
    C57BL/6 mouse splenocytes stained with CD4 (clone RM4-5) FITC (solid line) or rat IgG2a, κ FITC isotype control (dotted line).
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
100509 50 µg NOK248
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100510 500 µg NOK817
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes and a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a co-receptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
BALB/c mouse thymocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

The RM4-5 antibody blocks the binding of GK1.5 antibody and H129.19 antibody to CD4+ T cells, but not RM4-4 antibody. Additional reported applications (for the relevant formats) include: blocking of ligand binding, in vivo depletion of CD4+ cells1, and immunohistochemistry of acetone-fixed frozen tissue sections2,3,11 and paraffin-embedded sections11. Clone RM4-5 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. Instead, acetone frozen or zinc-fixed paraffin sections are recommended. The Ultra-LEAF™ Purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100575 and 100576).

Application References
  1. Kruisbeek AM. 1991. In Curr. Protocols Immunol. pp. 4.1.1-4.1.5. (Block, Deplete)
  2. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  3. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045.
  4. Muraille E, et al. 2003. Infect. Immun. 71:2704. (IHC)
  5. León-Ponte M, et al. 2007. Blood 109:3139. (FC)
  6. Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370. (FC)
  7. Matsumoto M, et al. 2007.J. Immunol.178:2499. PubMed
  8. Shigeta A, et al. 2008. Blood 112:4915. PubMed
  9. Zaborsky N, et al. 2010. J. Immunol. 184:725. PubMed
  10. Rodrigues-Manzanet R, et al. 2010. P. Natl Acad Sci USA 107:8706. PubMed
  11. Whiteland JL, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)
Product Citations
  1. Yu HH, et al. 2021. J Am Heart Assoc. 10:e023077. PubMed
  2. Aimaitijiang A, et al. 2022. Genes Cells. 27:25. PubMed
  3. Yu C, et al. 2022. Invest Ophthalmol Vis Sci. 63:1. PubMed
  4. Piñeros AR, et al. 2022. Cell Rep. 39:111011. PubMed
  5. Chen C, et al. 2022. Sci Adv. 8:eabo4363. PubMed
  6. Liu P, et al. 2023. Clin Immunol. 246:109212. PubMed
  7. Al-Saafeen BH, et al. 2023. Front Immunol. 13:1017780. PubMed
  8. Peng Q, et al. 2023. EMBO Rep. 24:e56034. PubMed
  9. Takacs GP, et al. 2023. Front Immunol. 13:993444. PubMed
  10. Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed
  11. Akhtar MN, et al. 2022. MBio. 13:e0330921. PubMed
  12. Cheng C, et al. 2022. Cell Mol Gastroenterol Hepatol. 15:261. PubMed
  13. Chen Y, et al. 2022. Am J Cancer Res. 12:5286. PubMed
  14. Han X, et al. 2022. Nutrients. 14:. PubMed
  15. Gao X, et al. 2023. Front Immunol. 14:1142428. PubMed
  16. Qin T, et al. 2023. Virol J. 20:75. PubMed
  17. Zhang YT, et al. 2023. Front Immunol. 14:1085456. PubMed
  18. Wang X, et al. 2023. NPJ Vaccines. 8:76. PubMed
  19. Stone VM, et al. 2022. iScience. 25:105070. PubMed
  20. Xu C, et al. 2017. Biochemical and Biophysical Research Communications. 10.1016/j.bbrc.2017.05.071. PubMed
  21. Wang L, et al. 2018. Exp Ther Med. 15:1532. PubMed
  22. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  23. Zhou J, et al. 2019. Immunity. 50:403. PubMed
  24. Fachi JL et al. 2019. Cell reports. 27(3):750-761 . PubMed
  25. Yang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  26. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  27. Li ZX, et al. 2022. Arch Virol. :. PubMed
  28. Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed
  29. Abou-Hamad J, et al. 2022. iScience. 25:105524. PubMed
  30. Kagoya Y, et al. 2018. Nat Commun. 9:1915. PubMed
  31. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  32. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  33. Gilleron J et al. 2018. Cell reports. 25(12):3329-3341 . PubMed
  34. Moodley D, et al. 2016. Proc Natl Acad Sci U S A. 113: 9852 - 9857. PubMed
  35. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  36. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  37. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 5:64. PubMed
  38. Achmus L, et al. 2020. Front Neurol. 11:577971. PubMed
  39. Yang W, et al. 2020. Nat Commun. 3.553472222. PubMed
  40. Lin H, et al. 2020. Front Microbiol. 1.330555556. PubMed
  41. Ogawa M, et al. 2019. J Biol Methods. 5:e102. PubMed
  42. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  43. Zheng H, et al. 2021. Frontiers in Cell and Developmental Biology. 9:641527. PubMed
  44. Sehnert B, et al. 2022. Front Immunol. 13:921488. PubMed
  45. Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed
  46. Jin X, et al. 2019. Mol Cell. 73:22:00. PubMed
  47. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  48. Zhao B, et al. 2021. Cell Reports. 36(3):109401. PubMed
  49. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  50. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
  51. Zhang C, et al. 2021. Clin Transl Immunology. 10:e1310. PubMed
  52. Wang C, et al. 2021. Cell Rep. 37:110021. PubMed
  53. Forni MF, et al. 2021. Front Oncol. 11:667715. PubMed
  54. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  55. Yi M, et al. 2021. J Hematol Oncol. 14:27. PubMed
  56. Wang Z, et al. 2021. J Virol. 95:e0141421. PubMed
  57. Graham DB, et al. 2018. Nat Med. 24:1762. PubMed
  58. Terashima Y, et al. 2020. Nat Commun. 11:609. PubMed
  59. Sundberg T, et al. 2014. Proc Natl Acad Sci U S A. 111:12468. PubMed
  60. Wiesner D, et al. 2015. PLoS Pathog. 11:1004701. PubMed
  61. Zhang L, et al. 2021. Methods Mol Biol. 2388:175. PubMed
  62. Gu Y, et al. 2021. Cell Res. Online ahead of print. PubMed
  63. Deng Z, et al. 2017. Oncogene. 36:639. PubMed
  64. Jackstadt R, et al. 2019. Cancer Cell. 36:319. PubMed
  65. Qi X, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.25. PubMed
  66. Repáraz D, et al. 2022. J Immunother Cancer. 10:. PubMed
  67. Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed
  68. Liao T, et al. 2017. Front Immunol. 8:1334. PubMed
  69. Spinner C, et al. 2015. Sci Rep. 5:16269. PubMed
  70. Mencarelli A, et al. 2016. Sci Rep. 6:30802. PubMed
  71. Gozgit JM, et al. 2021. Cancer Cell. :. PubMed
  72. Duan RN, et al. 2021. J Neuroinflammation. 18:145. PubMed
  73. Fang E, et al. 2022. MedComm (2020). 3:e117. PubMed
  74. Belgiovine C, et al. 2021. Eur J Immunol. 51:2677. PubMed
  75. Takeshita Y, et al. 2021. Neurol Neuroimmunol Neuroinflamm. 8:. PubMed
  76. Wan X, et al. 2018. Nature. 560:107. PubMed
  77. Wheeler MA, et al. 2019. Cell. 176:581. PubMed
  78. Kulkarni R, et al. 2021. PLoS One. 16:e0257191. PubMed
  79. Zhang YN, et al. 2020. EBioMedicine. 56:102819. PubMed
  80. Sebastian M, et al. 2016. J Immunol. 196: 144 - 155. PubMed
  81. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  82. Su X, et al. 2022. J Transl Med. 20:378. PubMed
  83. Anger-Góra N, et al. 2021. Oncol Lett. 22:582. PubMed
  84. Lischke T, et al. 2013. Infect Immun . 81:4091. PubMed
  85. Alhosaini K, et al. 2021. Brain Sci. :11. PubMed
  86. Lü X, et al. 2021. Exp Ther Med. 22:1005. PubMed
  87. Puigdelloses M, et al. 2021. J Immunother Cancer. 9:. PubMed
  88. Aguilera M, et al. 2021. Int J Mol Sci. 22:. PubMed
  89. Li Y, et al. 2021. Cell Death Dis. 12:1001. PubMed
  90. Kyburz A, et al. 2019. J Allergy Clin Immunol. 143:1496. PubMed
  91. Yi W, et al. 2021. Cell Reports. 34(13):108922. PubMed
  92. Chou T, et al. 2016. Nat Commun. 7:11904. PubMed
  93. Shiozawa S, et al. 2022. iScience. 25:103537. PubMed
  94. Chen C, et al. 2021. J Virol. 95:e0082921. PubMed
  95. Tu J, et al. 2022. Mol Ther Nucleic Acids. 27:733. PubMed
  96. Kyburz A, et al. 2017. Clin Exp Allergy. 47:1331. PubMed
  97. Dong M, et al. 2022. J Immunother Cancer. 10:. PubMed
  98. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  99. Stephens WZ, et al. 2021. Cell Rep. 37:109916. PubMed
  100. Kim M, et al. 2018. Immunity. 49:151. PubMed
  101. Papa I, et al. 2017. Nature. 547:318. PubMed
  102. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  103. Zhang J, et al. 2018. Nature. 553:91. PubMed
  104. Zhou X, et al. 2021. Cell Reports. 34(1):108601. PubMed
  105. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  106. Takenori Inomata, Jing Hua, Antonio Di Zazzo 2016. Sci Rep. 6:39924. PubMed
  107. Unsinger J, et al. 2021. J Leukoc Biol. 109:697. PubMed
  108. Uribe-Herranz M, et al. 2018. JCI Insight. 3. PubMed
  109. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  110. Richardson ET, et al. 2015. PLoS One. 10: 1371. PubMed
  111. Bell CR, et al. 2022. Nat Commun. 13:2063. PubMed
  112. de Assis LVM, et al. 2022. Commun Biol. 5:461. PubMed
  113. Bao Z, et al. 2020. Ann Transplant. 25:e921287. PubMed
  114. Cantor DJ et al. 2019. Cell reports. 26(1):108-118 . PubMed
  115. Lu J, et al. 2022. Int J Mol Med. 49:. PubMed
  116. Harrison DK, et al. 2021. Transplantation. 105:540. PubMed
  117. Zegarra‐Ruiz DF et al. 2018. Cell host & microbe. 25(1):113-127 . PubMed
  118. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 0.252777778. PubMed
  119. Wang X, et al. 2022. Elife. 11:. PubMed
  120. Leon-Ponte M, et al. 2006. Blood. 109:3139. PubMed
  121. Burton OT, et al. 2018. Clin Exp Allergy. 48:288. PubMed
  122. Yeon S, et al. 2017. Sci Rep. 10.1038/s41598-017-11492-7. PubMed
  123. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  124. Baptista M, et al. 2016. Nat Commun. 7:12175. PubMed
  125. Krotova K, et al. 2019. Mol Ther Oncolytics. 15:166. PubMed
  126. Helfricht A, et al. 2020. J Exp Med. 217:00:00. PubMed
  127. Ren D, et al. 2020. Am J Cancer Res. 2851:10. PubMed
  128. Wheeler MA, et al. 2020. Nature. 578:593. PubMed
  129. Siegmund K, et al. 2011. J Immunol. 186:3452. PubMed
  130. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  131. Ren X, et al. 2021. Cell Death Dis. 12:484. PubMed
  132. Rana MN, et al. 2021. Front Pharmacol. 12:643215. PubMed
  133. Chow AK, et al. 2021. Cellular and Molecular Gastroenterology and Hepatology. :. PubMed
  134. Gonzalez-Figueroa P, et al. 2021. Cell. 184(7):1775-1789.e19. PubMed
  135. Tripathi D, et al. 2016. Nat Commun. 7:13896. PubMed
  136. Campisi L, et al. 2016. Nat Immunol. 10.1038/ni.3512. PubMed
  137. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
  138. Yu HH, et al. 2021. J Am Heart Assoc. 10:e023077. PubMed
  139. Aimaitijiang A, et al. 2022. Genes Cells. 27:25. PubMed
  140. Yu C, et al. 2022. Invest Ophthalmol Vis Sci. 63:1. PubMed
  141. Piñeros AR, et al. 2022. Cell Rep. 39:111011. PubMed
  142. Chen C, et al. 2022. Sci Adv. 8:eabo4363. PubMed
  143. Liu P, et al. 2023. Clin Immunol. 246:109212. PubMed
  144. Al-Saafeen BH, et al. 2023. Front Immunol. 13:1017780. PubMed
  145. Peng Q, et al. 2023. EMBO Rep. 24:e56034. PubMed
  146. Takacs GP, et al. 2023. Front Immunol. 13:993444. PubMed
  147. Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed
  148. Akhtar MN, et al. 2022. MBio. 13:e0330921. PubMed
  149. Cheng C, et al. 2022. Cell Mol Gastroenterol Hepatol. 15:261. PubMed
  150. Chen Y, et al. 2022. Am J Cancer Res. 12:5286. PubMed
  151. Han X, et al. 2022. Nutrients. 14:. PubMed
  152. Gao X, et al. 2023. Front Immunol. 14:1142428. PubMed
  153. Qin T, et al. 2023. Virol J. 20:75. PubMed
  154. Zhang YT, et al. 2023. Front Immunol. 14:1085456. PubMed
  155. Wang X, et al. 2023. NPJ Vaccines. 8:76. PubMed
  156. Stone VM, et al. 2022. iScience. 25:105070. PubMed
  157. Xu C, et al. 2017. Biochemical and Biophysical Research Communications. 10.1016/j.bbrc.2017.05.071. PubMed
  158. Wang L, et al. 2018. Exp Ther Med. 15:1532. PubMed
  159. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  160. Zhou J, et al. 2019. Immunity. 50:403. PubMed
  161. Fachi JL et al. 2019. Cell reports. 27(3):750-761 . PubMed
  162. Yang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  163. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  164. Li ZX, et al. 2022. Arch Virol. :. PubMed
  165. Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed
  166. Abou-Hamad J, et al. 2022. iScience. 25:105524. PubMed
  167. Kagoya Y, et al. 2018. Nat Commun. 9:1915. PubMed
  168. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  169. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  170. Gilleron J et al. 2018. Cell reports. 25(12):3329-3341 . PubMed
  171. Moodley D, et al. 2016. Proc Natl Acad Sci U S A. 113: 9852 - 9857. PubMed
  172. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  173. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  174. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 5:64. PubMed
  175. Achmus L, et al. 2020. Front Neurol. 11:577971. PubMed
  176. Yang W, et al. 2020. Nat Commun. 3.553472222. PubMed
  177. Lin H, et al. 2020. Front Microbiol. 1.330555556. PubMed
  178. Ogawa M, et al. 2019. J Biol Methods. 5:e102. PubMed
  179. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  180. Zheng H, et al. 2021. Frontiers in Cell and Developmental Biology. 9:641527. PubMed
  181. Sehnert B, et al. 2022. Front Immunol. 13:921488. PubMed
  182. Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed
  183. Jin X, et al. 2019. Mol Cell. 73:22:00. PubMed
  184. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  185. Zhao B, et al. 2021. Cell Reports. 36(3):109401. PubMed
  186. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  187. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
  188. Zhang C, et al. 2021. Clin Transl Immunology. 10:e1310. PubMed
  189. Wang C, et al. 2021. Cell Rep. 37:110021. PubMed
  190. Forni MF, et al. 2021. Front Oncol. 11:667715. PubMed
  191. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  192. Yi M, et al. 2021. J Hematol Oncol. 14:27. PubMed
  193. Wang Z, et al. 2021. J Virol. 95:e0141421. PubMed
  194. Graham DB, et al. 2018. Nat Med. 24:1762. PubMed
  195. Terashima Y, et al. 2020. Nat Commun. 11:609. PubMed
  196. Sundberg T, et al. 2014. Proc Natl Acad Sci U S A. 111:12468. PubMed
  197. Wiesner D, et al. 2015. PLoS Pathog. 11:1004701. PubMed
  198. Zhang L, et al. 2021. Methods Mol Biol. 2388:175. PubMed
  199. Gu Y, et al. 2021. Cell Res. Online ahead of print. PubMed
  200. Deng Z, et al. 2017. Oncogene. 36:639. PubMed
  201. Jackstadt R, et al. 2019. Cancer Cell. 36:319. PubMed
  202. Qi X, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.25. PubMed
  203. Repáraz D, et al. 2022. J Immunother Cancer. 10:. PubMed
  204. Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed
  205. Liao T, et al. 2017. Front Immunol. 8:1334. PubMed
  206. Spinner C, et al. 2015. Sci Rep. 5:16269. PubMed
  207. Mencarelli A, et al. 2016. Sci Rep. 6:30802. PubMed
  208. Gozgit JM, et al. 2021. Cancer Cell. :. PubMed
  209. Duan RN, et al. 2021. J Neuroinflammation. 18:145. PubMed
  210. Fang E, et al. 2022. MedComm (2020). 3:e117. PubMed
  211. Belgiovine C, et al. 2021. Eur J Immunol. 51:2677. PubMed
  212. Takeshita Y, et al. 2021. Neurol Neuroimmunol Neuroinflamm. 8:. PubMed
  213. Wan X, et al. 2018. Nature. 560:107. PubMed
  214. Wheeler MA, et al. 2019. Cell. 176:581. PubMed
  215. Kulkarni R, et al. 2021. PLoS One. 16:e0257191. PubMed
  216. Zhang YN, et al. 2020. EBioMedicine. 56:102819. PubMed
  217. Sebastian M, et al. 2016. J Immunol. 196: 144 - 155. PubMed
  218. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  219. Su X, et al. 2022. J Transl Med. 20:378. PubMed
  220. Anger-Góra N, et al. 2021. Oncol Lett. 22:582. PubMed
  221. Lischke T, et al. 2013. Infect Immun . 81:4091. PubMed
  222. Alhosaini K, et al. 2021. Brain Sci. :11. PubMed
  223. Lü X, et al. 2021. Exp Ther Med. 22:1005. PubMed
  224. Puigdelloses M, et al. 2021. J Immunother Cancer. 9:. PubMed
  225. Aguilera M, et al. 2021. Int J Mol Sci. 22:. PubMed
  226. Li Y, et al. 2021. Cell Death Dis. 12:1001. PubMed
  227. Kyburz A, et al. 2019. J Allergy Clin Immunol. 143:1496. PubMed
  228. Yi W, et al. 2021. Cell Reports. 34(13):108922. PubMed
  229. Chou T, et al. 2016. Nat Commun. 7:11904. PubMed
  230. Shiozawa S, et al. 2022. iScience. 25:103537. PubMed
  231. Chen C, et al. 2021. J Virol. 95:e0082921. PubMed
  232. Tu J, et al. 2022. Mol Ther Nucleic Acids. 27:733. PubMed
  233. Kyburz A, et al. 2017. Clin Exp Allergy. 47:1331. PubMed
  234. Dong M, et al. 2022. J Immunother Cancer. 10:. PubMed
  235. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  236. Stephens WZ, et al. 2021. Cell Rep. 37:109916. PubMed
  237. Kim M, et al. 2018. Immunity. 49:151. PubMed
  238. Papa I, et al. 2017. Nature. 547:318. PubMed
  239. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  240. Zhang J, et al. 2018. Nature. 553:91. PubMed
  241. Zhou X, et al. 2021. Cell Reports. 34(1):108601. PubMed
  242. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  243. Takenori Inomata, Jing Hua, Antonio Di Zazzo 2016. Sci Rep. 6:39924. PubMed
  244. Unsinger J, et al. 2021. J Leukoc Biol. 109:697. PubMed
  245. Uribe-Herranz M, et al. 2018. JCI Insight. 3. PubMed
  246. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  247. Richardson ET, et al. 2015. PLoS One. 10: 1371. PubMed
  248. Bell CR, et al. 2022. Nat Commun. 13:2063. PubMed
  249. de Assis LVM, et al. 2022. Commun Biol. 5:461. PubMed
  250. Bao Z, et al. 2020. Ann Transplant. 25:e921287. PubMed
  251. Cantor DJ et al. 2019. Cell reports. 26(1):108-118 . PubMed
  252. Lu J, et al. 2022. Int J Mol Med. 49:. PubMed
  253. Harrison DK, et al. 2021. Transplantation. 105:540. PubMed
  254. Zegarra‐Ruiz DF et al. 2018. Cell host & microbe. 25(1):113-127 . PubMed
  255. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 0.252777778. PubMed
  256. Wang X, et al. 2022. Elife. 11:. PubMed
  257. Leon-Ponte M, et al. 2006. Blood. 109:3139. PubMed
  258. Burton OT, et al. 2018. Clin Exp Allergy. 48:288. PubMed
  259. Yeon S, et al. 2017. Sci Rep. 10.1038/s41598-017-11492-7. PubMed
  260. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  261. Baptista M, et al. 2016. Nat Commun. 7:12175. PubMed
  262. Krotova K, et al. 2019. Mol Ther Oncolytics. 15:166. PubMed
  263. Helfricht A, et al. 2020. J Exp Med. 217:00:00. PubMed
  264. Ren D, et al. 2020. Am J Cancer Res. 2851:10. PubMed
  265. Wheeler MA, et al. 2020. Nature. 578:593. PubMed
  266. Siegmund K, et al. 2011. J Immunol. 186:3452. PubMed
  267. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  268. Ren X, et al. 2021. Cell Death Dis. 12:484. PubMed
  269. Rana MN, et al. 2021. Front Pharmacol. 12:643215. PubMed
  270. Chow AK, et al. 2021. Cellular and Molecular Gastroenterology and Hepatology. :. PubMed
  271. Gonzalez-Figueroa P, et al. 2021. Cell. 184(7):1775-1789.e19. PubMed
  272. Tripathi D, et al. 2016. Nat Commun. 7:13896. PubMed
  273. Campisi L, et al. 2016. Nat Immunol. 10.1038/ni.3512. PubMed
  274. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
RRID
AB_312712 (BioLegend Cat. No. 100509)
AB_312713 (BioLegend Cat. No. 100510)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.

Other Formats

View All CD4 Reagents Request Custom Conjugation
Description Clone Applications
PE/Cyanine7 anti-mouse CD4 RM4-5 FC
APC/Cyanine7 anti-mouse CD4 RM4-5 FC
APC/Fire™ 750 anti-mouse CD4 RM4-5 FC
TotalSeq™-A0001 anti-mouse CD4 RM4-5 PG
TotalSeq™-B0001 anti-mouse CD4 RM4-5 PG
TotalSeq™-C0001 anti-mouse CD4 RM4-5 PG
Ultra-LEAF™ Purified anti-mouse CD4 RM4-5 FC,CyTOF®,Depletion,Block,IHC
APC anti-mouse CD4 RM4-5 FC
Biotin anti-mouse CD4 RM4-5 FC
FITC anti-mouse CD4 RM4-5 FC
PE anti-mouse CD4 RM4-5 FC
PE/Cyanine5 anti-mouse CD4 RM4-5 FC
Purified anti-mouse CD4 RM4-5 FC,CyTOF®,IHC-F,IHC
Alexa Fluor® 647 anti-mouse CD4 RM4-5 FC,3D IHC,IHC-F
Alexa Fluor® 488 anti-mouse CD4 RM4-5 FC,IHC-F,3D IHC
Pacific Blue™ anti-mouse CD4 RM4-5 FC
Alexa Fluor® 700 anti-mouse CD4 RM4-5 FC
PerCP anti-mouse CD4 RM4-5 FC
PerCP/Cyanine5.5 anti-mouse CD4 RM4-5 FC
Brilliant Violet 421™ anti-mouse CD4 RM4-5 FC,ICC,IHC-F
Brilliant Violet 570™ anti-mouse CD4 RM4-5 FC
Brilliant Violet 605™ anti-mouse CD4 RM4-5 FC
Brilliant Violet 650™ anti-mouse CD4 RM4-5 FC
Brilliant Violet 711™ anti-mouse CD4 RM4-5 FC
Brilliant Violet 785™ anti-mouse CD4 RM4-5 FC
Brilliant Violet 510™ anti-mouse CD4 RM4-5 FC
PE/Dazzle™ 594 anti-mouse CD4 RM4-5 FC
Purified anti-mouse CD4 (Maxpar® Ready) RM4-5 FC,CyTOF®
Spark Violet™ 423 anti-mouse CD4 RM4-5 FC
Spark Red™ 718 anti-mouse CD4 (Flexi-Fluor™) RM4-5 FC
APC/Fire™ 810 anti-mouse CD4 RM4-5 FC
PE/Fire™ 640 anti-mouse CD4 Antibody RM4-5 FC
Brilliant Violet 750™ anti-mouse CD4 Antibody RM4-5 FC
Spark YG™ 581 anti-mouse CD4 (Flexi-Fluor™) RM4-5 FC
StarBright UltraViolet 740 anti-mouse CD4 RM4-5 FC
Go To Top Version: 3    Revision Date: 01.29.2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
RM4-5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
RM4-5
C57BL/6 mouse splenocytes stained with CD4 (clone RM4-5) FITC (solid line) or rat IgG2a, κ FITC isotype control (dotted line).
  • RM4-5
    C57BL/6 mouse splenocytes stained with CD4 (clone RM4-5) FITC (solid line) or rat IgG2a, κ FITC isotype control (dotted line).
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
100509 50 µg NOK248
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100510 500 µg NOK817
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes and a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a co-receptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
BALB/c mouse thymocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

The RM4-5 antibody blocks the binding of GK1.5 antibody and H129.19 antibody to CD4+ T cells, but not RM4-4 antibody. Additional reported applications (for the relevant formats) include: blocking of ligand binding, in vivo depletion of CD4+ cells1, and immunohistochemistry of acetone-fixed frozen tissue sections2,3,11 and paraffin-embedded sections11. Clone RM4-5 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. Instead, acetone frozen or zinc-fixed paraffin sections are recommended. The Ultra-LEAF™ Purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100575 and 100576).

Application References
  1. Kruisbeek AM. 1991. In Curr. Protocols Immunol. pp. 4.1.1-4.1.5. (Block, Deplete)
  2. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  3. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045.
  4. Muraille E, et al. 2003. Infect. Immun. 71:2704. (IHC)
  5. León-Ponte M, et al. 2007. Blood 109:3139. (FC)
  6. Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370. (FC)
  7. Matsumoto M, et al. 2007.J. Immunol.178:2499. PubMed
  8. Shigeta A, et al. 2008. Blood 112:4915. PubMed
  9. Zaborsky N, et al. 2010. J. Immunol. 184:725. PubMed
  10. Rodrigues-Manzanet R, et al. 2010. P. Natl Acad Sci USA 107:8706. PubMed
  11. Whiteland JL, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)
Product Citations
  1. Yu HH, et al. 2021. J Am Heart Assoc. 10:e023077. PubMed
  2. Aimaitijiang A, et al. 2022. Genes Cells. 27:25. PubMed
  3. Yu C, et al. 2022. Invest Ophthalmol Vis Sci. 63:1. PubMed
  4. Piñeros AR, et al. 2022. Cell Rep. 39:111011. PubMed
  5. Chen C, et al. 2022. Sci Adv. 8:eabo4363. PubMed
  6. Liu P, et al. 2023. Clin Immunol. 246:109212. PubMed
  7. Al-Saafeen BH, et al. 2023. Front Immunol. 13:1017780. PubMed
  8. Peng Q, et al. 2023. EMBO Rep. 24:e56034. PubMed
  9. Takacs GP, et al. 2023. Front Immunol. 13:993444. PubMed
  10. Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed
  11. Akhtar MN, et al. 2022. MBio. 13:e0330921. PubMed
  12. Cheng C, et al. 2022. Cell Mol Gastroenterol Hepatol. 15:261. PubMed
  13. Chen Y, et al. 2022. Am J Cancer Res. 12:5286. PubMed
  14. Han X, et al. 2022. Nutrients. 14:. PubMed
  15. Gao X, et al. 2023. Front Immunol. 14:1142428. PubMed
  16. Qin T, et al. 2023. Virol J. 20:75. PubMed
  17. Zhang YT, et al. 2023. Front Immunol. 14:1085456. PubMed
  18. Wang X, et al. 2023. NPJ Vaccines. 8:76. PubMed
  19. Stone VM, et al. 2022. iScience. 25:105070. PubMed
  20. Xu C, et al. 2017. Biochemical and Biophysical Research Communications. 10.1016/j.bbrc.2017.05.071. PubMed
  21. Wang L, et al. 2018. Exp Ther Med. 15:1532. PubMed
  22. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  23. Zhou J, et al. 2019. Immunity. 50:403. PubMed
  24. Fachi JL et al. 2019. Cell reports. 27(3):750-761 . PubMed
  25. Yang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  26. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  27. Li ZX, et al. 2022. Arch Virol. :. PubMed
  28. Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed
  29. Abou-Hamad J, et al. 2022. iScience. 25:105524. PubMed
  30. Kagoya Y, et al. 2018. Nat Commun. 9:1915. PubMed
  31. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  32. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  33. Gilleron J et al. 2018. Cell reports. 25(12):3329-3341 . PubMed
  34. Moodley D, et al. 2016. Proc Natl Acad Sci U S A. 113: 9852 - 9857. PubMed
  35. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  36. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  37. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 5:64. PubMed
  38. Achmus L, et al. 2020. Front Neurol. 11:577971. PubMed
  39. Yang W, et al. 2020. Nat Commun. 3.553472222. PubMed
  40. Lin H, et al. 2020. Front Microbiol. 1.330555556. PubMed
  41. Ogawa M, et al. 2019. J Biol Methods. 5:e102. PubMed
  42. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  43. Zheng H, et al. 2021. Frontiers in Cell and Developmental Biology. 9:641527. PubMed
  44. Sehnert B, et al. 2022. Front Immunol. 13:921488. PubMed
  45. Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed
  46. Jin X, et al. 2019. Mol Cell. 73:22:00. PubMed
  47. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  48. Zhao B, et al. 2021. Cell Reports. 36(3):109401. PubMed
  49. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  50. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
  51. Zhang C, et al. 2021. Clin Transl Immunology. 10:e1310. PubMed
  52. Wang C, et al. 2021. Cell Rep. 37:110021. PubMed
  53. Forni MF, et al. 2021. Front Oncol. 11:667715. PubMed
  54. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  55. Yi M, et al. 2021. J Hematol Oncol. 14:27. PubMed
  56. Wang Z, et al. 2021. J Virol. 95:e0141421. PubMed
  57. Graham DB, et al. 2018. Nat Med. 24:1762. PubMed
  58. Terashima Y, et al. 2020. Nat Commun. 11:609. PubMed
  59. Sundberg T, et al. 2014. Proc Natl Acad Sci U S A. 111:12468. PubMed
  60. Wiesner D, et al. 2015. PLoS Pathog. 11:1004701. PubMed
  61. Zhang L, et al. 2021. Methods Mol Biol. 2388:175. PubMed
  62. Gu Y, et al. 2021. Cell Res. Online ahead of print. PubMed
  63. Deng Z, et al. 2017. Oncogene. 36:639. PubMed
  64. Jackstadt R, et al. 2019. Cancer Cell. 36:319. PubMed
  65. Qi X, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.25. PubMed
  66. Repáraz D, et al. 2022. J Immunother Cancer. 10:. PubMed
  67. Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed
  68. Liao T, et al. 2017. Front Immunol. 8:1334. PubMed
  69. Spinner C, et al. 2015. Sci Rep. 5:16269. PubMed
  70. Mencarelli A, et al. 2016. Sci Rep. 6:30802. PubMed
  71. Gozgit JM, et al. 2021. Cancer Cell. :. PubMed
  72. Duan RN, et al. 2021. J Neuroinflammation. 18:145. PubMed
  73. Fang E, et al. 2022. MedComm (2020). 3:e117. PubMed
  74. Belgiovine C, et al. 2021. Eur J Immunol. 51:2677. PubMed
  75. Takeshita Y, et al. 2021. Neurol Neuroimmunol Neuroinflamm. 8:. PubMed
  76. Wan X, et al. 2018. Nature. 560:107. PubMed
  77. Wheeler MA, et al. 2019. Cell. 176:581. PubMed
  78. Kulkarni R, et al. 2021. PLoS One. 16:e0257191. PubMed
  79. Zhang YN, et al. 2020. EBioMedicine. 56:102819. PubMed
  80. Sebastian M, et al. 2016. J Immunol. 196: 144 - 155. PubMed
  81. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  82. Su X, et al. 2022. J Transl Med. 20:378. PubMed
  83. Anger-Góra N, et al. 2021. Oncol Lett. 22:582. PubMed
  84. Lischke T, et al. 2013. Infect Immun . 81:4091. PubMed
  85. Alhosaini K, et al. 2021. Brain Sci. :11. PubMed
  86. Lü X, et al. 2021. Exp Ther Med. 22:1005. PubMed
  87. Puigdelloses M, et al. 2021. J Immunother Cancer. 9:. PubMed
  88. Aguilera M, et al. 2021. Int J Mol Sci. 22:. PubMed
  89. Li Y, et al. 2021. Cell Death Dis. 12:1001. PubMed
  90. Kyburz A, et al. 2019. J Allergy Clin Immunol. 143:1496. PubMed
  91. Yi W, et al. 2021. Cell Reports. 34(13):108922. PubMed
  92. Chou T, et al. 2016. Nat Commun. 7:11904. PubMed
  93. Shiozawa S, et al. 2022. iScience. 25:103537. PubMed
  94. Chen C, et al. 2021. J Virol. 95:e0082921. PubMed
  95. Tu J, et al. 2022. Mol Ther Nucleic Acids. 27:733. PubMed
  96. Kyburz A, et al. 2017. Clin Exp Allergy. 47:1331. PubMed
  97. Dong M, et al. 2022. J Immunother Cancer. 10:. PubMed
  98. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  99. Stephens WZ, et al. 2021. Cell Rep. 37:109916. PubMed
  100. Kim M, et al. 2018. Immunity. 49:151. PubMed
  101. Papa I, et al. 2017. Nature. 547:318. PubMed
  102. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  103. Zhang J, et al. 2018. Nature. 553:91. PubMed
  104. Zhou X, et al. 2021. Cell Reports. 34(1):108601. PubMed
  105. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  106. Takenori Inomata, Jing Hua, Antonio Di Zazzo 2016. Sci Rep. 6:39924. PubMed
  107. Unsinger J, et al. 2021. J Leukoc Biol. 109:697. PubMed
  108. Uribe-Herranz M, et al. 2018. JCI Insight. 3. PubMed
  109. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  110. Richardson ET, et al. 2015. PLoS One. 10: 1371. PubMed
  111. Bell CR, et al. 2022. Nat Commun. 13:2063. PubMed
  112. de Assis LVM, et al. 2022. Commun Biol. 5:461. PubMed
  113. Bao Z, et al. 2020. Ann Transplant. 25:e921287. PubMed
  114. Cantor DJ et al. 2019. Cell reports. 26(1):108-118 . PubMed
  115. Lu J, et al. 2022. Int J Mol Med. 49:. PubMed
  116. Harrison DK, et al. 2021. Transplantation. 105:540. PubMed
  117. Zegarra‐Ruiz DF et al. 2018. Cell host & microbe. 25(1):113-127 . PubMed
  118. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 0.252777778. PubMed
  119. Wang X, et al. 2022. Elife. 11:. PubMed
  120. Leon-Ponte M, et al. 2006. Blood. 109:3139. PubMed
  121. Burton OT, et al. 2018. Clin Exp Allergy. 48:288. PubMed
  122. Yeon S, et al. 2017. Sci Rep. 10.1038/s41598-017-11492-7. PubMed
  123. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  124. Baptista M, et al. 2016. Nat Commun. 7:12175. PubMed
  125. Krotova K, et al. 2019. Mol Ther Oncolytics. 15:166. PubMed
  126. Helfricht A, et al. 2020. J Exp Med. 217:00:00. PubMed
  127. Ren D, et al. 2020. Am J Cancer Res. 2851:10. PubMed
  128. Wheeler MA, et al. 2020. Nature. 578:593. PubMed
  129. Siegmund K, et al. 2011. J Immunol. 186:3452. PubMed
  130. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  131. Ren X, et al. 2021. Cell Death Dis. 12:484. PubMed
  132. Rana MN, et al. 2021. Front Pharmacol. 12:643215. PubMed
  133. Chow AK, et al. 2021. Cellular and Molecular Gastroenterology and Hepatology. :. PubMed
  134. Gonzalez-Figueroa P, et al. 2021. Cell. 184(7):1775-1789.e19. PubMed
  135. Tripathi D, et al. 2016. Nat Commun. 7:13896. PubMed
  136. Campisi L, et al. 2016. Nat Immunol. 10.1038/ni.3512. PubMed
  137. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
  138. Yu HH, et al. 2021. J Am Heart Assoc. 10:e023077. PubMed
  139. Aimaitijiang A, et al. 2022. Genes Cells. 27:25. PubMed
  140. Yu C, et al. 2022. Invest Ophthalmol Vis Sci. 63:1. PubMed
  141. Piñeros AR, et al. 2022. Cell Rep. 39:111011. PubMed
  142. Chen C, et al. 2022. Sci Adv. 8:eabo4363. PubMed
  143. Liu P, et al. 2023. Clin Immunol. 246:109212. PubMed
  144. Al-Saafeen BH, et al. 2023. Front Immunol. 13:1017780. PubMed
  145. Peng Q, et al. 2023. EMBO Rep. 24:e56034. PubMed
  146. Takacs GP, et al. 2023. Front Immunol. 13:993444. PubMed
  147. Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed
  148. Akhtar MN, et al. 2022. MBio. 13:e0330921. PubMed
  149. Cheng C, et al. 2022. Cell Mol Gastroenterol Hepatol. 15:261. PubMed
  150. Chen Y, et al. 2022. Am J Cancer Res. 12:5286. PubMed
  151. Han X, et al. 2022. Nutrients. 14:. PubMed
  152. Gao X, et al. 2023. Front Immunol. 14:1142428. PubMed
  153. Qin T, et al. 2023. Virol J. 20:75. PubMed
  154. Zhang YT, et al. 2023. Front Immunol. 14:1085456. PubMed
  155. Wang X, et al. 2023. NPJ Vaccines. 8:76. PubMed
  156. Stone VM, et al. 2022. iScience. 25:105070. PubMed
  157. Xu C, et al. 2017. Biochemical and Biophysical Research Communications. 10.1016/j.bbrc.2017.05.071. PubMed
  158. Wang L, et al. 2018. Exp Ther Med. 15:1532. PubMed
  159. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  160. Zhou J, et al. 2019. Immunity. 50:403. PubMed
  161. Fachi JL et al. 2019. Cell reports. 27(3):750-761 . PubMed
  162. Yang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  163. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  164. Li ZX, et al. 2022. Arch Virol. :. PubMed
  165. Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed
  166. Abou-Hamad J, et al. 2022. iScience. 25:105524. PubMed
  167. Kagoya Y, et al. 2018. Nat Commun. 9:1915. PubMed
  168. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  169. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  170. Gilleron J et al. 2018. Cell reports. 25(12):3329-3341 . PubMed
  171. Moodley D, et al. 2016. Proc Natl Acad Sci U S A. 113: 9852 - 9857. PubMed
  172. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  173. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  174. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 5:64. PubMed
  175. Achmus L, et al. 2020. Front Neurol. 11:577971. PubMed
  176. Yang W, et al. 2020. Nat Commun. 3.553472222. PubMed
  177. Lin H, et al. 2020. Front Microbiol. 1.330555556. PubMed
  178. Ogawa M, et al. 2019. J Biol Methods. 5:e102. PubMed
  179. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  180. Zheng H, et al. 2021. Frontiers in Cell and Developmental Biology. 9:641527. PubMed
  181. Sehnert B, et al. 2022. Front Immunol. 13:921488. PubMed
  182. Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed
  183. Jin X, et al. 2019. Mol Cell. 73:22:00. PubMed
  184. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  185. Zhao B, et al. 2021. Cell Reports. 36(3):109401. PubMed
  186. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  187. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
  188. Zhang C, et al. 2021. Clin Transl Immunology. 10:e1310. PubMed
  189. Wang C, et al. 2021. Cell Rep. 37:110021. PubMed
  190. Forni MF, et al. 2021. Front Oncol. 11:667715. PubMed
  191. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  192. Yi M, et al. 2021. J Hematol Oncol. 14:27. PubMed
  193. Wang Z, et al. 2021. J Virol. 95:e0141421. PubMed
  194. Graham DB, et al. 2018. Nat Med. 24:1762. PubMed
  195. Terashima Y, et al. 2020. Nat Commun. 11:609. PubMed
  196. Sundberg T, et al. 2014. Proc Natl Acad Sci U S A. 111:12468. PubMed
  197. Wiesner D, et al. 2015. PLoS Pathog. 11:1004701. PubMed
  198. Zhang L, et al. 2021. Methods Mol Biol. 2388:175. PubMed
  199. Gu Y, et al. 2021. Cell Res. Online ahead of print. PubMed
  200. Deng Z, et al. 2017. Oncogene. 36:639. PubMed
  201. Jackstadt R, et al. 2019. Cancer Cell. 36:319. PubMed
  202. Qi X, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.25. PubMed
  203. Repáraz D, et al. 2022. J Immunother Cancer. 10:. PubMed
  204. Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed
  205. Liao T, et al. 2017. Front Immunol. 8:1334. PubMed
  206. Spinner C, et al. 2015. Sci Rep. 5:16269. PubMed
  207. Mencarelli A, et al. 2016. Sci Rep. 6:30802. PubMed
  208. Gozgit JM, et al. 2021. Cancer Cell. :. PubMed
  209. Duan RN, et al. 2021. J Neuroinflammation. 18:145. PubMed
  210. Fang E, et al. 2022. MedComm (2020). 3:e117. PubMed
  211. Belgiovine C, et al. 2021. Eur J Immunol. 51:2677. PubMed
  212. Takeshita Y, et al. 2021. Neurol Neuroimmunol Neuroinflamm. 8:. PubMed
  213. Wan X, et al. 2018. Nature. 560:107. PubMed
  214. Wheeler MA, et al. 2019. Cell. 176:581. PubMed
  215. Kulkarni R, et al. 2021. PLoS One. 16:e0257191. PubMed
  216. Zhang YN, et al. 2020. EBioMedicine. 56:102819. PubMed
  217. Sebastian M, et al. 2016. J Immunol. 196: 144 - 155. PubMed
  218. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  219. Su X, et al. 2022. J Transl Med. 20:378. PubMed
  220. Anger-Góra N, et al. 2021. Oncol Lett. 22:582. PubMed
  221. Lischke T, et al. 2013. Infect Immun . 81:4091. PubMed
  222. Alhosaini K, et al. 2021. Brain Sci. :11. PubMed
  223. Lü X, et al. 2021. Exp Ther Med. 22:1005. PubMed
  224. Puigdelloses M, et al. 2021. J Immunother Cancer. 9:. PubMed
  225. Aguilera M, et al. 2021. Int J Mol Sci. 22:. PubMed
  226. Li Y, et al. 2021. Cell Death Dis. 12:1001. PubMed
  227. Kyburz A, et al. 2019. J Allergy Clin Immunol. 143:1496. PubMed
  228. Yi W, et al. 2021. Cell Reports. 34(13):108922. PubMed
  229. Chou T, et al. 2016. Nat Commun. 7:11904. PubMed
  230. Shiozawa S, et al. 2022. iScience. 25:103537. PubMed
  231. Chen C, et al. 2021. J Virol. 95:e0082921. PubMed
  232. Tu J, et al. 2022. Mol Ther Nucleic Acids. 27:733. PubMed
  233. Kyburz A, et al. 2017. Clin Exp Allergy. 47:1331. PubMed
  234. Dong M, et al. 2022. J Immunother Cancer. 10:. PubMed
  235. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  236. Stephens WZ, et al. 2021. Cell Rep. 37:109916. PubMed
  237. Kim M, et al. 2018. Immunity. 49:151. PubMed
  238. Papa I, et al. 2017. Nature. 547:318. PubMed
  239. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  240. Zhang J, et al. 2018. Nature. 553:91. PubMed
  241. Zhou X, et al. 2021. Cell Reports. 34(1):108601. PubMed
  242. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  243. Takenori Inomata, Jing Hua, Antonio Di Zazzo 2016. Sci Rep. 6:39924. PubMed
  244. Unsinger J, et al. 2021. J Leukoc Biol. 109:697. PubMed
  245. Uribe-Herranz M, et al. 2018. JCI Insight. 3. PubMed
  246. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  247. Richardson ET, et al. 2015. PLoS One. 10: 1371. PubMed
  248. Bell CR, et al. 2022. Nat Commun. 13:2063. PubMed
  249. de Assis LVM, et al. 2022. Commun Biol. 5:461. PubMed
  250. Bao Z, et al. 2020. Ann Transplant. 25:e921287. PubMed
  251. Cantor DJ et al. 2019. Cell reports. 26(1):108-118 . PubMed
  252. Lu J, et al. 2022. Int J Mol Med. 49:. PubMed
  253. Harrison DK, et al. 2021. Transplantation. 105:540. PubMed
  254. Zegarra‐Ruiz DF et al. 2018. Cell host & microbe. 25(1):113-127 . PubMed
  255. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 0.252777778. PubMed
  256. Wang X, et al. 2022. Elife. 11:. PubMed
  257. Leon-Ponte M, et al. 2006. Blood. 109:3139. PubMed
  258. Burton OT, et al. 2018. Clin Exp Allergy. 48:288. PubMed
  259. Yeon S, et al. 2017. Sci Rep. 10.1038/s41598-017-11492-7. PubMed
  260. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  261. Baptista M, et al. 2016. Nat Commun. 7:12175. PubMed
  262. Krotova K, et al. 2019. Mol Ther Oncolytics. 15:166. PubMed
  263. Helfricht A, et al. 2020. J Exp Med. 217:00:00. PubMed
  264. Ren D, et al. 2020. Am J Cancer Res. 2851:10. PubMed
  265. Wheeler MA, et al. 2020. Nature. 578:593. PubMed
  266. Siegmund K, et al. 2011. J Immunol. 186:3452. PubMed
  267. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
  268. Ren X, et al. 2021. Cell Death Dis. 12:484. PubMed
  269. Rana MN, et al. 2021. Front Pharmacol. 12:643215. PubMed
  270. Chow AK, et al. 2021. Cellular and Molecular Gastroenterology and Hepatology. :. PubMed
  271. Gonzalez-Figueroa P, et al. 2021. Cell. 184(7):1775-1789.e19. PubMed
  272. Tripathi D, et al. 2016. Nat Commun. 7:13896. PubMed
  273. Campisi L, et al. 2016. Nat Immunol. 10.1038/ni.3512. PubMed
  274. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
RRID
AB_312712 (BioLegend Cat. No. 100509)
AB_312713 (BioLegend Cat. No. 100510)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.

Other Formats

View All CD4 Reagents Request Custom Conjugation
Description Clone Applications
PE/Cyanine7 anti-mouse CD4 RM4-5 FC
APC/Cyanine7 anti-mouse CD4 RM4-5 FC
APC/Fire™ 750 anti-mouse CD4 RM4-5 FC
TotalSeq™-A0001 anti-mouse CD4 RM4-5 PG
TotalSeq™-B0001 anti-mouse CD4 RM4-5 PG
TotalSeq™-C0001 anti-mouse CD4 RM4-5 PG
Ultra-LEAF™ Purified anti-mouse CD4 RM4-5 FC,CyTOF®,Depletion,Block,IHC
APC anti-mouse CD4 RM4-5 FC
Biotin anti-mouse CD4 RM4-5 FC
FITC anti-mouse CD4 RM4-5 FC
PE anti-mouse CD4 RM4-5 FC
PE/Cyanine5 anti-mouse CD4 RM4-5 FC
Purified anti-mouse CD4 RM4-5 FC,CyTOF®,IHC-F,IHC
Alexa Fluor® 647 anti-mouse CD4 RM4-5 FC,3D IHC,IHC-F
Alexa Fluor® 488 anti-mouse CD4 RM4-5 FC,IHC-F,3D IHC
Pacific Blue™ anti-mouse CD4 RM4-5 FC
Alexa Fluor® 700 anti-mouse CD4 RM4-5 FC
PerCP anti-mouse CD4 RM4-5 FC
PerCP/Cyanine5.5 anti-mouse CD4 RM4-5 FC
Brilliant Violet 421™ anti-mouse CD4 RM4-5 FC,ICC,IHC-F
Brilliant Violet 570™ anti-mouse CD4 RM4-5 FC
Brilliant Violet 605™ anti-mouse CD4 RM4-5 FC
Brilliant Violet 650™ anti-mouse CD4 RM4-5 FC
Brilliant Violet 711™ anti-mouse CD4 RM4-5 FC
Brilliant Violet 785™ anti-mouse CD4 RM4-5 FC
Brilliant Violet 510™ anti-mouse CD4 RM4-5 FC
PE/Dazzle™ 594 anti-mouse CD4 RM4-5 FC
Purified anti-mouse CD4 (Maxpar® Ready) RM4-5 FC,CyTOF®
Spark Violet™ 423 anti-mouse CD4 RM4-5 FC
Spark Red™ 718 anti-mouse CD4 (Flexi-Fluor™) RM4-5 FC
APC/Fire™ 810 anti-mouse CD4 RM4-5 FC
PE/Fire™ 640 anti-mouse CD4 Antibody RM4-5 FC
Brilliant Violet 750™ anti-mouse CD4 Antibody RM4-5 FC
Spark YG™ 581 anti-mouse CD4 (Flexi-Fluor™) RM4-5 FC
StarBright UltraViolet 740 anti-mouse CD4 RM4-5 FC
Go To Top Version: 3    Revision Date: 01.29.2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account